131 related articles for article (PubMed ID: 38173289)
1. Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
Ozawa Y; Nohara S; Nakamura K; Hattori S; Yagi Y; Nishiyama T; Yorozu A; Monma T; Saito S
Prostate; 2024 Apr; 84(5):502-510. PubMed ID: 38173289
[TBL] [Abstract][Full Text] [Related]
2. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
3. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
[TBL] [Abstract][Full Text] [Related]
4. Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers.
Meynard C; Huertas A; Dariane C; Toublanc S; Dubourg Q; Urien S; Timsit MO; Méjean A; Thiounn N; Giraud P
Radiat Oncol; 2019 Dec; 15(1):1. PubMed ID: 31892338
[TBL] [Abstract][Full Text] [Related]
5. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
6. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.
Kestin LL; Goldstein NS; Vicini FA; Martinez AA
J Urol; 2002 Nov; 168(5):1994-9. PubMed ID: 12394693
[TBL] [Abstract][Full Text] [Related]
7. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
Cancer J; 2005; 11(3):234-40. PubMed ID: 16053667
[TBL] [Abstract][Full Text] [Related]
8. Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy.
Kestin LL; Goldstein NS; Vicini FA; Mitchell C; Gustafson GS; Stromberg JS; Chen PY; Martinez AA
Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):107-18. PubMed ID: 12182980
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external-beam radiation.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
Cancer J; 2004; 10(1):54-60. PubMed ID: 15000496
[TBL] [Abstract][Full Text] [Related]
10. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
[TBL] [Abstract][Full Text] [Related]
11. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Gleason Score ≤ 8 among high risk prostate cancer treated with 125I low dose rate brachytherapy based multimodal therapy.
Park DS; Gong IH; Choi DK; Hwang JH; Shin HS; Oh JJ
Yonsei Med J; 2013 Sep; 54(5):1207-13. PubMed ID: 23918571
[TBL] [Abstract][Full Text] [Related]
13. Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer.
Takamoto A; Tanimoto R; Bekku K; Araki M; Sadahira T; Wada K; Ebara S; Katayama N; Yanai H; Nasu Y
Int J Urol; 2018 May; 25(5):507-512. PubMed ID: 29651796
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
15. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer].
Martínez PF; Belisle DF; Cristallo C; Tobía I; Damia O; Villamil W; Giudice CR
Arch Esp Urol; 2015 Oct; 68(8):655-60. PubMed ID: 26437328
[TBL] [Abstract][Full Text] [Related]
17. Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence.
Gretzer MB; Epstein JI; Pound CR; Walsh PC; Partin AW
Urology; 2002 Dec; 60(6):1034-9. PubMed ID: 12475665
[TBL] [Abstract][Full Text] [Related]
18. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
[TBL] [Abstract][Full Text] [Related]
19. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
20. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
